Cardiovascular Systems Stock
Your prediction
Pros and Cons of Cardiovascular Systems in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cardiovascular Systems vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cardiovascular Systems | - | - | - | - | - | - | - |
| Atricure Inc. | 2.960% | 4.819% | 24.286% | -43.871% | -43.871% | -43.871% | -11.224% |
| Orasure Tech | 1.870% | 2.830% | 2.830% | -43.229% | -36.257% | -55.328% | -79.434% |
| SI-BONE Inc | 0.630% | -5.917% | 2.581% | 22.308% | 22.308% | - | - |
News
Boston Sci Q2 Revenue Up 23%
Boston Scientific (NYSE:BSX), a leading medical device maker known for its heart and surgical products, released second-quarter results on July 23, 2025. Revenue reached $5.06 billion for Q2 2025
Boston Sci Q2 Revenue Up 23 Percent
Boston Scientific (NYSE:BSX), a leader in medical devices for cardiovascular and surgical markets, reported its second-quarter 2025 results on July 23, 2025. The company posted revenue and earnings